Albumin-bilirubin grade as a prognostic indicator for patients with non-hepatocellular primary and metastatic liver malignancy undergoing Yttrium-90 radioembolization using resin microspheres.

BACKGROUND: Studies have shown that the albumin-bilirubin (ALBI) grade can be a superior prognosticator for patients undergoing Yttrium-90 (Y90) glass microsphere radioembolization for hepatocellular carcinoma (HCC) compared to the Child-Pugh (CP) scoring system. Less is known about the applicability of this score in non-hepatocellular malignancies using Y90 resin microspheres. This study evaluates the ALBI grade's ability to predict overall survival and biochemical toxicity in patients undergoing resin Y90 radioembolization and body surface area dosimetry (BSA) for non-hepatocellular primary and metastatic liver malignancies compared to the CP class and Model for End-Stage Liver Disease (MELD) score. METHODS: A retrospective review of patients with intrahepatic metastatic colorectal and neuroendocrine cancers and cholangiocarcinoma undergoing resin radioembolization from 2006-2015 at a single tertiary medical center was performed. ALBI, MELD, and CP scores were compared and correlated with biochemical toxicity and overall survival. RESULTS: There was a significant difference in overall survival between CP class A and class B liver function (P=0.04) for the entire patient cohort. ALBI grade (P=0.36) and MELD score (P=0.19) were not independently associated with survival. When stratified by CP class, the ALBI grade revealed a trend for survival difference in CP class B (P=0.05). Baseline ALBI grade was associated with post-procedural albumin reduction (P=0.01) and bilirubin elevation (P=0.007). CONCLUSIONS: ALBI grade predicted post-procedural biochemical toxicity, but did not predict survival after resin radioembolization of non-hepatocellular liver malignancies using BSA dosimetry. Given the heterogeneity of this study population, dedicated prospective analyses are required.

Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience.

BACKGROUND: Many patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed with liver metastatic disease (mPDAC), and few are surgical candidates. Interventional oncology (IO) locoregional therapies (LRT) have proven beneficial in other primary and metastatic hepatic malignancies. Systemic chemotherapy is the standard of care for patients with mPDAC. This study assessed the safety and efficacy of LRT including thermal ablation, chemoembolization, and radioembolization for mPDAC. METHODS: A retrospective analysis was performed of 28 patients with mPDAC referred to IR clinic for consideration of LRT from 01/2006 to 08/2017, of whom 20 underwent treatment. Laboratory values were analyzed at 0, 3, and 6 months post-treatment. Imaging response was evaluated at 1, 3, and 6 months post-intervention by modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. Adverse events (AE) were classified by CTCAE v5.0. Overall survival (OS) from the diagnosis of PDAC, survival from the time of mPDAC diagnosis, and survival from the time of LRT were calculated. RESULTS: Median OS (mOS) was 25 months. Median survival from time of mPDAC diagnosis and post LRT were 16.25 and 9.7 months, respectively. At one month post-intervention, 12 of 17 patients demonstrated disease response (CR or PR per mRECIST). Survival among responders was 9 months vs. 6 months for patients with stable or progressive disease (P=0.08). There were two grade 3 AE which included post-embolization syndrome and transient renal failure. Chemotherapy was briefly delayed in one of these patients, but ultimately resumed. CONCLUSIONS: The use of LRT in patients with mPDAC is safe. Additionally, no significant chemotherapy limiting toxicities were observed. Responders to therapy demonstrated a survival benefit trend in this small and heterogeneous cohort. Further investigations with randomized trials are warranted.

Biometria ocular, estimativa matemática e variação esférica pós-facectomia / Ocular biometry, mathematical estimation and spherical variation after facectomy

RESUMO Objetivo: Avaliar os parâmetros biométricos oculares por meio da biometria óptica e observar uma possível diferença refratométrica esférica, assim como sua variação, baseada no cálculo pré-cirúrgico estimado e na refração esférica pós-cirurgia de catarata pela facoemulsificação com implante de lente intraocular (LIO). Métodos: Foram revisados 252 prontuários eletrônicos entre 2013 e 2014 dos quais foram selecionados 117 pacientes adultos (189 olhos) submetidos à facoemulsificação com implante de LIO dobrável pelo mesmo cirurgião e examinados através do IOLMaster® 500. O poder dióptrico da LIO foi calculado pela fórmula de Haigis. O teste de Wilcoxon foi empregado para testar a existência de diferença significativa (p<0,05) entre o grau esférico esperado (GEE) e o grau esférico final (GEF). Resultados: Foram operados 98 olhos direitos (OD) e 91 esquerdos (OE). Após calculada a variação entre o GEE e o GEF observou-se que 55% dos OD alcançaram resultados dentro de ± 0,5 dioptrias (D) e 89% resultados dentro de ± 1D. Quanto ao OE, 46% alcançaram resultados dentro de ± 0,5D e 78% dentro de ± 1D. Conclusão: A biometria óptica pode ser utilizada como um método confiável, previsível e reprodutível para que seja estimado o GEF de ambos olhos.

ABSTRACT Objective: To assess ocular biometric parameters by optical biometry and to observe a possible spherical refractive difference, as well as its variation based on estimated preoperative calculation and the spherical refraction post cataract surgery by phacoemulsification with intraocular lens implant (IOL). Methods: After reviewing 252 electronic medical records between 2013 and 2014, 117 adult patients (189 eyes) were selected.The patients underwent phacoemulsification with foldable IOL implantation by the same surgeon and were examined by IOLMaster® 500.The IOL power was calculated using the Haigis formula.The Wilcoxon test was applied to identify the existence of significant differences (p<0.05) between the spherical expected refraction (SER) and the final spherical refraction (FSR) of the eyes. Results: There were operated 98 right eyes (OD) and 91 left (OS). A calculation of the variation between FSR and SER indicated that 55% of the OD reached results within ± 0.5 diopters (D) and 89% within ± 1D. With respect to OS, 46% achieved results within ± 0.5D and 78% within ± 1D. Conclusion: Optical biometry is a reliable, predictable and reproducible method to estimate the FSR of both eyes.